Date: 2015-12-01
Type of information: Licensing agreement
Compound: Vascular Adhesion Protein 1 (VAP-1) inhibitor
Company: Roche (Switzerland) Upsher-Smith Laboratories (USA - MN)
Therapeutic area:
Type agreement: licensing
Action mechanism: VAP-1 inhibitor
Disease:
Details: * On December 1, 2015, Roche and Upsher-Smith Laboratories, through its wholly-owned UK subsidiary Proximagen Ltd., announced a worldwide agreement for the further development of a novel, oral small molecule inhibitor of Vascular Adhesion Protein 1 (VAP-1), a cell-adhesion molecule that may be effective in the treatment of inflammatory diseases. The VAP-1 inhibitor is currently in phase II clinical development. Under the terms of the agreement, Roche is granted a worldwide exclusive license to develop and commercialize the compound. In a novel collaboration model, Roche and Proximagen will conduct additional phase II studies to further define the therapeutic potential of the VAP-1 inhibitor. Based on these data Roche will assume responsibility for late stage development and worldwide commercialization.
The transaction is subject to the expiration or early termination of the applicable U.S. Hart-Scott-Rodino waiting period.
Financial terms: Proximagen will receive an upfront payment, along with downstream development, regulatory and sales milestones. In addition, Proximagen will also receive tiered royalties on net sales of a potential future product containing the molecule.
Latest news:
